261 research outputs found

    A Study of Transport Behaviour of Academic Communities

    Get PDF
    n important challenge to achieving sustainable university campuses is ensuring that the academic community makes sustainable transport choices. The objective of this study was to investigate the daily commuting patterns, identify the potential for change, and determine the factors and criteria affecting the transport decisions of academic communities of two universities located in Gdansk, Poland. This paper summarizes the results of trip generation measurements and a comprehensive online survey of 3678 respondents, including the universities&rsquo staff and students. Analysis of survey results revealed clear differences between students and university staff in terms of travel patterns and factors that influence their choices. Staff usually (57%) choose the car for daily commutes with students opting for public transport (59%). The choice of travel mode in particular groups is determined mostly by car availability, trip origin location, and accessibility. The choices also depend on transport user individual requirements such as trip quality, costs, or ecology. With approximately 1400 trips daily per 1000 students, the universities are large traffic generators. Thus, how the staff and students behave determines the effect the universities have on the urban transport system. Understanding the behaviour can help to estimate whether it can be changed and how. Document type: Articl

    Location-Based Games as a Contemporary, Original, and Innovative Method of SeniorsÔÇÖ Teaching and Learning

    Get PDF
    This book is a result of the Location-based games as a contemporary, original, and innovative method of seniorsÔÇÖ teaching and learning [LoGaSET] project, coordinated by Foundation Pro Scientia Publica, financed from the Erasmus Plus KA2 strategic partnership budget (nr 2017-1-PL01-KA204-038869). Dr Ewa Jurczyk-Romanowska (University of Wroc┼éaw, Poland) was the scientific coordinator of the project

    Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data

    Get PDF
    Background: In Poland, treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has become available free of charge in a therapeutic program. Assessed herein, is the efficacy and safety of alirocumab and evolocumab in patients with heterozygous familial hypercholesterolemia (FH).Methods: Data of 55 adult FH patients who participated in the program were analyzed upon meeting the criteria established by the Ministry of Health (low density lipoprotein cholesterol [LDL-C] above 160 mg/dL on max. tolerated statin dose and ezetimib). The efficacy of PCSK9 inhibitors in reducing LDL-C with drug administration every 2 weeks was assessed after 3 months and 1 year of therapy. A safety profile evaluation was performed at each visit. 48 patients completed the 3-month and 21 for the 1-year observation periods (34 patients treated with alirokumab and 14 with evolocumab).Results: The mean concentration of direct-measured LDL-C decreased from the initial level of 215.1 ┬▒ 74.5 mg/dL to 75.3 ┬▒ 64.1 mg/dL, i.e., by 65 ┬▒ 14% following 3 months of treatment. This effect was stable in 1-year observation (77.7 ┬▒ 72.8 mg/dL). Adverse effects were flu-like symptoms (13.0%), injection site reactions (11.1%), fatigue (5.6%) and musculoskeletal symptoms (5.6%). Seven patients failed to complete the 3-month treatment period due to side effects or non-compliance, and 1 patient failed to complete the 1-year treatment due to myalgia.Conclusions: This study confirmed high effectiveness of PCSK9 inhibitors in reducing LDL-C levels in patients with FH. Due to restrictive inclusion criteria with LDL-C threshold level > 160 mg/dL (> 4.1 mmol/L) required for participation in the therapeutic program, a relatively small number of FH patients were eligible for treatment

    The Pediatric Choroidal and Ciliary Body Melanoma Study A Survey by the European Ophthalmic Oncology Group

    Get PDF
    Purpose: To collect comprehensive data on choroidal and ciliary body melanoma (CCBM) in children and to validate hypotheses regarding pediatric CCBM: children younger than 18 years, males, and those without ciliary body involvement (CBI) have more favorable survival prognosis than young adults 18 to 24 years of age, females, and those with CBI. Design: Retrospective, multicenter observational study. Participants: Two hundred ninety-nine patients from 24 ocular oncology centers, of whom 114 were children (median age, 15.1 years; range, 2.7-17.9 years) and 185 were young adults. Methods: Data were entered through a secure website and were reviewed centrally. Survival was analyzed using Kaplan-Meier analysis and Cox proportional hazards regression. Main Outcome Measures: Proportion of females, tumor-node-metastasis (TNM) stage, cell type, and melanoma-related mortality. Results: Cumulative frequency of having CCBM diagnosed increased steadily by 0.8% per year of age between 5 and 10 years of age and, after a 6-year transition period, by 8.8% per year from age 17 years onward. Of children and young adults, 57% and 63% were female, respectively, which exceeded the expected 51% among young adults. Cell type, known for 35% of tumors, and TNM stage (I in 22% and 21%, II in 49% and 52%, III in 30% and 28%, respectively) were comparable for children and young adults. Melanoma-related survival was 97% and 90% at 5 years and 92% and 80% at 10 years for children compared with young adults, respectively (P = 0.013). Males tended to have a more favorable survival than females among children (100% vs. 85% at 10 years; P = 0.058). Increasing TNM stage was associated with poorer survival (stages I, II, and III: 100% vs. 86% vs. 76%, respectively; P = 0.0011). By multivariate analysis, being a young adult (adjusted hazard rate [HR], 2.57), a higher TNM stage (HR, 2.88 and 8.38 for stages II and III, respectively), and female gender (HR, 2.38) independently predicted less favorable survival. Ciliary body involvement and cell type were not associated with survival. Conclusions: This study confirms that children with CCBM have a more favorable survival than young adults 18 to 25 years of age, adjusting for TNM stage and gender. The association between gender and survival varies between age groups. (C) 2016 by the American Academy of Ophthalmology.Peer reviewe

    Działania opiekuńcze w profilaktyce i terapii

    Get PDF
    Praca recenzowana / Peer-reviewed paperOpieka jest potrzebna wszystkim, zar├│wno dzieciom, jak i doros┼éym, a w spos├│b szczeg├│lny osobom starszym, w tym terminalnie chorym. Prezentowane w niniejszej monografi i teksty uwzgl─Ödniaj─ů w┼éa┼Ťnie t─Ö wieloczynnikow─ů aktywno┼Ť─ç opieku┼äcz─ů. Autorami poszczeg├│lnych rozdzia┼é├│w s─ů pracownicy naukowi zaanga┼╝owani w proces edukacyjny w zakresie nauk o zdrowiu, pracuj─ůcy w Krakowskiej Akademii im. Andrzeja Frycza Modrzewskiego, ale tak┼╝e studenci PWSZ w Tarnowie. W r├│┼╝norodnym zakresie przedstawili i om├│wili oni g┼é├│wne tezy monografii

    Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    Get PDF
    Background: Approximately 450ÔÇë000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2┬Ě1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13┬Ě0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63ÔÇë093 individuals in the FHSC registry, 11ÔÇë848 (18┬Ě8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50┬Ě2%) of 11ÔÇë476 included individuals were female and 5720 (49┬Ě8%) were male. Sex data were missing for 372 (3┬Ě1%) of 11ÔÇë848 individuals. Median age at registry entry was 9┬Ě6 years (IQR 5┬Ě8-13┬Ě2). 10ÔÇë099 (89┬Ě9%) of 11ÔÇë235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10┬Ě1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5┬Ě2%) of 11ÔÇë848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92┬Ě4%] of 10ÔÇë202) than in children and adolescents from non-high-income countries (199 [48┬Ě0%] of 415). 3414 (31┬Ě6%) of 10ÔÇë804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72┬Ě4%) of 10ÔÇë428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5┬Ě00 mmol/L (IQR 4┬Ě05-6┬Ě08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

    Optimasi Portofolio Resiko Menggunakan Model Markowitz MVO Dikaitkan dengan Keterbatasan Manusia dalam Memprediksi Masa Depan dalam Perspektif Al-Qur`an

    Full text link
    Risk portfolio on modern finance has become increasingly technical, requiring the use of sophisticated mathematical tools in both research and practice. Since companies cannot insure themselves completely against risk, as human incompetence in predicting the future precisely that written in Al-Quran surah Luqman verse 34, they have to manage it to yield an optimal portfolio. The objective here is to minimize the variance among all portfolios, or alternatively, to maximize expected return among all portfolios that has at least a certain expected return. Furthermore, this study focuses on optimizing risk portfolio so called Markowitz MVO (Mean-Variance Optimization). Some theoretical frameworks for analysis are arithmetic mean, geometric mean, variance, covariance, linear programming, and quadratic programming. Moreover, finding a minimum variance portfolio produces a convex quadratic programming, that is minimizing the objective function ├░├░┬ąwith constraints├░ ├░ ├░┬ą ┬ą ├░and├░┬┤├░┬ą = ├░. The outcome of this research is the solution of optimal risk portofolio in some investments that could be finished smoothly using MATLAB R2007b software together with its graphic analysis

    Measurement of the top quark mass using charged particles in pp collisions at root s=8 TeV